Check Before You Invest : Infinium Pharmachem Ltd

Q: Which industry/sub-sector does Infinium Pharmachem Ltd belong to?

Infinium Pharmachem Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Chemicals segment.

Q: Is Infinium Pharmachem Ltd a good quality company?

Infinium Pharmachem Ltd is a good quality company, based on a consistently good multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Infinium Pharmachem Ltd undervalued or overvalued?

Infinium Pharmachem Ltd appears Undervalued, as its key valuation ratios are lower than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 38.81, Historic Median: 37.28. Price to Book, Current: 3.11, Historic Median: 5.80. Price to Sales, Current: 2.4, Historic Median: 3.01. EV to EBITDA, Current: 19.68, Historic Median: 20.75

Q: Is Infinium Pharmachem Ltd a good buy now?

Infinium Pharmachem Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd revenue growth is 11.9% for FY-2025, which is below its 5-year CAGR of 30.6%, indicating slower growth.

Q: Gross Profit margin of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.7% for FY-2025, which is in line with its 5-year median of 10.8%, indicating stable margins.

Q: Operating Profit Margin of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 11.09% for FY-2025, which is below its 5-year median of 11.78% indicating decreasing margins.

Q: Net Profit Margin of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Net Profit Margin is 6.19% for FY-2025, is below its 5-year median of 7.43%, indicating decreasing margins. Profitability Metrics. Gross Profit Margin (%), Current: 10.7, Historic Median: 10.8. Operating Profit Margin (%), Current: 11.09, Historic Median: 11.78. Net Profit Margin (%), Current: 6.19, Historic Median: 7.43

Q: Return on Asset of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Return on Asset is 6.95%, which is below its 5-year historical median of 13.8%, indicating deteriorated asset utilization efficiency.

Q: Return on capital employed (ROCE) of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Return on capital employed is 13.22% for FY-2025, which is below its 5-year historical median of 31.77%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Check Before You Invest : Infinium Pharmachem Ltd

Snapshot

Q.1 Which industry/sub-sector does Infinium Pharmachem Ltd belong to?

Infinium Pharmachem Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Chemicals segment.

Q.2 Is Infinium Pharmachem Ltd a good quality company?

Infinium Pharmachem Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Infinium Pharmachem Ltd undervalued or overvalued?

Infinium Pharmachem Ltd appears Undervalued, as its key valuation ratios are lower than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	38.81	37.28
Price to Book	3.11	5.80
Price to Sales	2.4	3.01
EV to EBITDA	19.68	20.75

Q.4 Is Infinium Pharmachem Ltd a good buy now?

Infinium Pharmachem Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd revenue growth is 11.9% for FY-2025, which is below its 5-year CAGR of 30.6%, indicating slower growth.

Q.2 Gross Profit margin of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.7% for FY-2025, which is in line with its 5-year median of 10.8%, indicating stable margins.

Q.3 Operating Profit Margin of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 11.09% for FY-2025, which is below its 5-year median of 11.78% indicating decreasing margins.

Q.4 Net Profit Margin of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Net Profit Margin is 6.19% for FY-2025, is below its 5-year median of 7.43%, indicating decreasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	10.7	10.8
Operating Profit Margin (%)	11.09	11.78
Net Profit Margin (%)	6.19	7.43

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Return on Asset is 6.95%, which is below its 5-year historical median of 13.8%, indicating deteriorated asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Return on capital employed is 13.22% for FY-2025, which is below its 5-year historical median of 31.77%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.7 Return on Equity (ROE) of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Return on equity is 10.36% for FY-2025, which is below its 5-year historical median of 47.87%, indicating the business is making worse use of its shareholders capital.

Q.8 Cash conversion cycle of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Cash conversion cycle is 127 days, above its 5-year historical median of 68 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	1.12	1.85
ROE (%)	10.36	47.87
ROCE (%)	13.22	31.77
Cash Conversion Cycle	127 days	68 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Debt-to-Equity ratio is 0.43, which is above the industry average of 0.13, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Infinium Pharmachem Ltd?

Infinium Pharmachem Ltd Debt to cash flow from operations is -1.75, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Infinium Pharmachem Ltd?

Q.1 Promoter shareholding and pledge status of Infinium Pharmachem Ltd?

Promoters hold 64.91% of the Infinium Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Infinium Pharmachem Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Infinium Pharmachem Ltd vs industry peers?

Infinium Pharmachem Ltd revenue CAGR is 30.60%, compared to the industry median CAGR of 7.53%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	11.9	7.5
Gross Profit Growth (%)	-11.8	12.1
Operating Profit Growth (%)	-11.8	11.7
Net Profit Growth (%)	-27.3	9.7

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	1.12	0.93
ROE (%)	10.36	10.17
ROCE (%)	13.22	12.96
Cash Conversion Cycle (days)	126.96	62

Valuation & price assessment

Q.1 Stock return of Infinium Pharmachem Ltd over the last decade?

Over the last 3 year(s), the stock has delivered a CAGR of -8.31% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-8.3%	-33.3%

Q.2 Valuation ratios of Infinium Pharmachem Ltd vs historical?

The current P/E ratio of 38.81 is in line with than its historical median of 37.28, indicating that the stock is trading near its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	38.81	37.28	28.17
Price to Book	3.11	5.80	2.22
Price to Sales	2.4	3.01	1.93
EV to EBITDA	19.68	20.75	14.20

Check more companies

1. Godrej Industries

2. Navin Fluorine Intl.

3. Deepak Nitrite

4. Deepak Fert & Petro

5. Atul

6. Aether Industries

7. Tata Chemicals

8. Aarti Industries

9. Fine Organic Inds.

10. BASF India

Check trending companies

1. CG Power and Industrial Solutions Ltd.

2. Solar Industries India Ltd.

3. IndusInd Bank Ltd.

4. 360 One Wam Ltd.

5. Pidilite Industries Ltd.

Check Before You Invest : Infinium Pharmachem Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.